[Survey of the Effect of Adding Aprepitant at the First Treatment of Regimens Containing Carboplatin on Antiemetic Efficacy].

In the Guidelines for the Appropriate Use of Antiemetic Drugs published in 2023, antiemetic drugs for regimens containing carboplatin(CBDCA)with an area under the blood concentration time curve(AUC)of ≥4 is recommended for neurokinin 1(NK1)receptor antagonists. However, the antiemetic efficacy of aprepitant(APR)has not been adequately evaluated. Therefore, we investigated whether the addition of APR in gynecological cancer CBDCA/paclitaxel(PAC)therapy (TCb therapy)with or without APR influenced the overall treatment rate of emetic control, nausea control rate, emetic complete response(CR rate)and total control rate of nausea and vomiting(total complete: TC rate)were to be investigated. The results showed that the emesis control rate, nausea control rate, CR rate and TC rate were similar with and without concomitant APR. In other words, the addition of APR was not significant for nausea and vomiting in cancer chemotherapy during the first treatment of regimens including CBDCA in gynecological cancer patients.